PMID- 24322180
OWN - NLM
STAT- MEDLINE
DCOM- 20140325
LR  - 20211021
IS  - 1432-1335 (Electronic)
IS  - 0171-5216 (Linking)
VI  - 140
IP  - 2
DP  - 2014 Feb
TI  - Induction of antigen-specific immune responses by dendritic cells transduced with 
      a recombinant lentiviral vector encoding MAGE-A3 gene.
PG  - 281-9
LID - 10.1007/s00432-013-1552-8 [doi]
AB  - PURPOSE: Melanoma antigen gene A3 (MAGE-A3) is aberrantly expressed in a number 
      of cancer types. Because of its high specificity, MAGE-A3 has shown to be a 
      promising candidate for cancer immunotherapy. Dendritic cells (DCs) have emerged 
      as the natural agents for antigen delivery. DCs transduced with antigen may 
      increase immune response and maintain immune durability. The aim of this study 
      was to investigate the roles of DCs transduced with lentiviral vectors (LVs) 
      encoding full-length MAGE-A3 gene in cancer immunotherapy . METHODS: A LV 
      containing full-length MAGE-A3 gene (rLV/MAGE-A3) was constructed. Reverse 
      transcriptase-polymerase chain reaction and direct DNA sequencing were performed 
      to verify the construct. Human DCs derived from umbilical cord blood were then 
      transduced with rLV/MAGE-A3. The potency of rLV/MAGE-A3-transduced DCs was 
      examined by measurement of surface markers and mixed lymphocyte reaction. The 
      MAGE-A3-specific T-cell response induced by DCs was detected using the lactate 
      dehydrogenase release assay. RESULTS: rLV/MAGE-A3 was constructed successfully 
      and used to transduce DCs efficiently. DCs transduced with rLV/MAGE-A3 stably 
      expressed MAGE-A3 and yielded high percentage of cells expressing CD80, CD86, and 
      HLA-DR. rLV/MAGE-A3 transduction did not impair DCs viability and maturation at a 
      multiplicity of infection of 30. The rLV/MAGE-A3-transduced DCs induced 
      MAGE-A3-specific T lymphocytes that exhibited a significant lysis activity 
      against MAGE-A3-bearing tumor cell lines (HuH-7 and SGC-7901). CONCLUSIONS: 
      DC-directed rLV/MAGE-A3 efficiently induced antigen-specific immune responses, 
      indicating the possibility of DC-based MAGE-A3 antigen vaccine as a promising 
      strategy for treatment of MAGE-A3-associated cancer.
FAU - Lin, Liyan
AU  - Lin L
AD  - Department of Pathology, Fujian Medical University, 88# Jiao Tong Road, Fuzhou, 
      350004, Fujian, People's Republic of China.
FAU - Wei, Juanbing
AU  - Wei J
FAU - Chen, Yuqing
AU  - Chen Y
FAU - Huang, Aimin
AU  - Huang A
FAU - Li, Kay Ka-Wai
AU  - Li KK
FAU - Zhang, Wenmin
AU  - Zhang W
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20131210
PL  - Germany
TA  - J Cancer Res Clin Oncol
JT  - Journal of cancer research and clinical oncology
JID - 7902060
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Cancer Vaccines)
RN  - 0 (MAGEA3 protein, human)
RN  - 0 (Neoplasm Proteins)
RN  - 0 (RNA, Messenger)
SB  - IM
MH  - Antigens, Neoplasm/genetics/*immunology/metabolism
MH  - Blotting, Western
MH  - Cancer Vaccines/*administration & dosage/immunology
MH  - Carcinoma, Hepatocellular/genetics/*immunology/therapy
MH  - Cell Proliferation
MH  - Cells, Cultured
MH  - Dendritic Cells/cytology/*immunology/metabolism
MH  - Flow Cytometry
MH  - Hepatocytes/*immunology/metabolism
MH  - Humans
MH  - Immunotherapy
MH  - Lentivirus/genetics
MH  - Liver Neoplasms/genetics/*immunology/therapy
MH  - Neoplasm Proteins/genetics/*immunology/metabolism
MH  - RNA, Messenger/genetics
MH  - Real-Time Polymerase Chain Reaction
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Stomach Neoplasms/genetics/*immunology/therapy
MH  - T-Lymphocytes/immunology/metabolism
EDAT- 2013/12/11 06:00
MHDA- 2014/03/26 06:00
CRDT- 2013/12/11 06:00
PHST- 2013/06/12 00:00 [received]
PHST- 2013/11/14 00:00 [accepted]
PHST- 2013/12/11 06:00 [entrez]
PHST- 2013/12/11 06:00 [pubmed]
PHST- 2014/03/26 06:00 [medline]
AID - 10.1007/s00432-013-1552-8 [doi]
PST - ppublish
SO  - J Cancer Res Clin Oncol. 2014 Feb;140(2):281-9. doi: 10.1007/s00432-013-1552-8. 
      Epub 2013 Dec 10.